Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04387084 · ClinicalTrials.gov registry record · Phase 1
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
A Phase 1 study of Metastatic Malignant Skin Neoplasm and Advanced Malignant Skin Neoplasm, sponsored by University of Southern California.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT04387084 is a Phase 1 study of Metastatic Malignant Skin Neoplasm and Advanced Malignant Skin Neoplasm that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 10 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT04387084, a Phase 1 study of Metastatic Malignant Skin Neoplasm and Advanced Malignant Skin Neoplasm, is active but no longer recruiting, sponsored by University of Southern California.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial studies the side effects of short-term fasting in patients with skin malignancy that has spread to other places in the body (advanced or metastatic) treated with a PD-L1 or PD-1 inhibitor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, nivolumab, cemiplimab, avelumab, atezolizumab, or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Undergoing short-term fasting prior to treatment with one of these PD-L1 or PD-1 inhibitors may potentially reduce the side effects of immunotherapy or even improve the effectiveness of immunotherapy in patients with skin malignancy.
Conditions Studied
Interventions
- DRUG Atezolizumab
- BIOLOGICAL Durvalumab
- BIOLOGICAL Cemiplimab
- BIOLOGICAL Nivolumab
- DRUG Avelumab
Study Locations (2)
California
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2027-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04387084
The ClinicalTrials.gov registry entry for NCT04387084 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Malignant Skin Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.
NCT04387084 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04387084 about?
NCT04387084 is a clinical study titled "Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy". This trial studies the side effects of short-term fasting in patients with skin malignancy that has spread to other places in the body (advanced or metastatic) treated with a PD-L1 or PD-1 inhibitor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, nivolumab, cemiplimab, avelumab, at...
What is the current status of trial NCT04387084?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-08-12. Estimated completion is 2027-08-12.
What conditions does trial NCT04387084 study?
This clinical trial studies the following conditions: Metastatic Malignant Skin Neoplasm, Advanced Malignant Skin Neoplasm.
What interventions are being tested in trial NCT04387084?
The interventions under investigation include: Atezolizumab (DRUG), Durvalumab (BIOLOGICAL), Cemiplimab (BIOLOGICAL), Nivolumab (BIOLOGICAL), Avelumab (DRUG).
Who is sponsoring clinical trial NCT04387084?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04387084 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Skin Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic Malignant Skin Neoplasm
All registered trials for this condition
Advanced Malignant Skin Neoplasm
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.